Thinness obsession prompts diet drug misuse in South Korea
A wave of demand for weight-loss medication is sweeping South Korea, a country that remains one of the OECD’s leanest, as rising body-image pressure and easy access fuel misuse that concerns health authorities. At the same time, a new generation of oral GLP-1 medications is expected to enter the Korean market as early as next year, setting the stage for further growth. Eli Lilly’s oral GLP-1 agonist orforglipron may launch in Korea next year once it receives approval from the US Food and Drug Administration, according to media reports on Sunday. Also under review is Novo Nordisk’s 25-milligram oral semaglutide. […]...Keep on reading: Thinness obsession prompts diet drug misuse in South Korea
